News & Updates
Filter by Specialty:
Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?
Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.
Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?
05 May 2022
Oncoplastic surgery boosts quality of life in breast cancer patients
In women with breast cancer, oncoplastic surgery improves quality of life and is associated with high patient satisfaction, reports a new study.
Oncoplastic surgery boosts quality of life in breast cancer patients
04 May 2022
Statins confer some protection against breast cancer recurrence in Asians
Taking a statin after breast cancer surgery appears to reduce the risk of disease recurrence in Asians, especially among those with invasive cancers, as shown in a study from Singapore.
Statins confer some protection against breast cancer recurrence in Asians
04 May 2022
New HF guideline: Quad therapy, HFmrEF, and more
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.
New HF guideline: Quad therapy, HFmrEF, and more
04 May 2022
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.